Atopic Dermatitis: Insights on Pathogenesis, Evaluation and Management

Karagiannidou A¹, Botskariova S¹, Farmaki E², Imvrios G² and Mavroudi A¹*

¹Third Pediatric Department of the Aristotle University of Thessaloniki, Greece
²First Pediatric Department of the Aristotle University of Thessaloniki, Greece

Abstract

Background: Atopic Dermatitis (AD) is a highly pruritic chronic inflammatory skin disease that commonly presents during early childhood. Several studies indicate that the disease is very common in western world with lifetime prevalence in children of 10% to 20%.

Data sources: We make recommendations regarding the evaluation and management of AD in children based on systematic literature searches using the best-available evidence from PubMed, Medline, Google Scholar, NICE, the American Academy of Dermatology and the World Allergy Organization.

Results: AD has an immunologic basis. Both innate and adaptive immune responses are impaired in AD patients. Intense pruritus is a hallmark of the disease which leads to extensive scratching and further breakdown of the skin barrier. Treatment of AD may be topical or systemic. Topical corticosteroids and calcineurin inhibitors are used as topical anti-inflammatory agents. Patients should be carefully instructed in the use of topical glucocorticoids to avoid side effects.

Conclusions: Treatment of atopic eczema should be based on a "stepped-care plan" where treatments are stepped up or down depending on the assessment of the state of the child’s skin by the physician. Physicians who treat children with mild to moderate AD should tell children and their caregivers that AD is a lifelong illness.

Keywords: Atopic dermatitis; Eczema; Evaluation; Management; Children

Introduction

Atopic Dermatitis (AD) is a highly pruritic chronic inflammatory skin disease that commonly presents during early childhood and is often thought as synonymous with eczema. In several cases atopic dermatitis is the first manifestation of atopy and is frequently associated with personal and family history of respiratory allergy and have profound effects on patient’s lives, career, choices and social interactions. According to the recommendation of the World Allergy Organization in 2004, the general term for a local inflammation of the skin should be “dermatitis”, while proposing the term “eczema” to replace the term previously used as “syndrome eczema/dermatitis” [3]. They also recommend limiting the use of the term “atopic eczema” when a mediation IgE is demonstrated in the pathophysiology of the disease, and “non-atopic eczema” when it is discarded [4].

Epidemiology

Several studies indicate that the disease is very common in Western world with lifetime prevalence in children of 10% to 20% [5,6]. There has been a culmination of a twofold to threefold increase in the prevalence of AD since the 1970s.

Genetics

The risk that the disorder will be genetically transmitted is increased when the mother is affected. There has been considerable interest in the potential role of chromosome 3q 31-33 as it contains a clustered family of cytokine genes that is IL-3, IL-4, IL-5, IL-13, and GM-CSF, which are expressed by Th2 cells [7]. Case control comparisons have suggested a genotypic association between T allele of the -590C/T polymorphism of the IL-4 gene promoter region and AD. The fact that this allele is expressed by Th2 cells suggests a potential role of chromosome 5q 31-33 as it contains a clustered family of cytokine genes that is IL-3, IL-4, IL-5, IL-13, and GM-CSF, which are expressed by Th2 cells [7].

3q21 in families of German and Scandinavian children [11]. This region may contribute to increased skin inflammation.

Chromosomal polymorphism in the mast cell chymase gene and AD that has no association with asthma or allergic rhinitis has been identified [7,9]. This finding suggests that a genetic variant of mast cell chymase, which is a serine protease secreted by mast cells, may have organ specific-effects and contribute to the genetic susceptibility for AD. AD has also been associated with a low-producer transforming growth factor beta cytokine genotype [10]. Because transforming growth factor beta is an important regulatory gene that down-regulates T cell activation, a low production genotype may contribute to increased skin inflammation.

A study by Turner et al. reports a linkage for AD on chromosome 3q21 in families of German and Scandinavian children [11]. This region encodes the costimulatory molecules CD80 and CD86 and therefore

Keywords: Atopic dermatitis; Eczema; Evaluation; Management; Children

Received August 27, 2014; Accepted October 06, 2014; Published October 13, 2014


Copyright: © 2014 Karagiannidou A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
may modulate T cell responses. Another screening study by Cookson et al. [12,13] reported linkage of AD to loci on chromosomes 1q21, 17q25 and 20p. Interestingly, these same regions are known to contain psoriasis susceptibility genes, which suggests common candidate genes involved in the control of skin inflammation. This suggests that AD is influenced by genes that modulate skin responses independent of allergic mechanisms.

Pathogenesis

Interactions between susceptibility genes, the host’s environment and immunologic factors contribute to the pathogenesis of AD. Although most genetic studies have focused on immunological mechanisms, a primary epithelial barrier defect has been anticipated. Filaggrin is a key protein that facilitates terminal differentiation of the epidermis and formation of the skin barrier. It has been shown that two independent loss-of-function genetic variants (R510X and 2282del14) in the gene encoding filaggrin are very strong predisposing factors for atopic dermatitis [14]. Filaggrin is the main source of several major components of natural moisturizing factor of the stratum corneum including pyrrolidone carboxylic acid and urocanic acid. A reduced level of pyrrolidone carboxylic acid and urocanic acid in patients with filaggrin deficiency may be regarded an expected finding [15]. The notion that AD has an immunologic basis is supported by the observation that primary T cell immunodeficiency disorders are frequently associated with elevated serum IgE levels and eczematoid lesions.

Systemic Immune Response

In patients with AD both innate and adaptive immune responses are impaired. Intense pruritus is a hallmark of AD which inevitably leads to extensive scratching and ultimately further breakdown of the skin barrier. It is clear that an intact and functional skin barrier (stratum corneum) is required for an effective cutaneous innate immune response. Pattern-recognition receptors- composed of mannann-binding lectins and surfactant proteins recognize unique sugars present on both gram-positive and gram-negative bacteria, fungi, and viruses. They can act directly as opsonins by coating the pathogen and making them accessible for phagocytosis or they can directly activate the complement pathway. Mannann-binding lectin deficiency has been shown to predispose individuals to bacterial and viral infections, including HSV and S. aureus. It was reported that a mutation in the Toll-Like Receptor 2 gene R753Q was found with increased frequency in patients with AD and that it was correlated with more severe phenotype, higher serum total IgE levels, and greater susceptibility to S. aureus colonization [16].

The IL-1 receptor pathway has been implicated for defective host immune response to S. aureus probably due to impaired neutrophil chemotaxis in response to S. aureus. Because inflammatory skin disease are known to be exacerbated by stress, it can be hypothesized that the stress-induced release of corticotrophin-releasing hormone and the ensuing reduction of IL-18 and IL-1β levels might also play a role in the susceptibility to cutaneous infections in patients with AD [17].

Children with AD have been shown to have reduced levels of soluble CD14 compared with non-atopic children. The lower levels of soluble CD14 observed in children with AD might be due to a reduced capacity to respond to microbial signal [18].

A study demonstrated that the sweat of subjects with AD was deficient in antimicrobial peptides compared with the sweat of healthy subjects. The antimicrobial properties of these peptides arise from their ability to integrate into and disrupt the cellular membrane of the offending organism [19].

Studies have demonstrated various poly-morphonuclear defects in subjects with AD. These include impaired phagocytic function and a reduced capacity to produce reactive oxygen species. Additionally patients with AD had defective poly-morphonuclear chemotactic activity which correlated with the disease severity and the presence of cutaneous infections [20].

In the peripheral blood of patients with AD increased homing T cells producing interleukin (IL)-4, IL-5, and IL-13 but little interferon (INF)-γ have been found. These immunologic alterations are important because IL-4 and IL-13 are the only cytokines that induce germ line transcription at the Cε exon, thereby promoting isotype switching to IgE. IL-4 and IL-13 also induce the expression of vascular adhesion molecule-1 involved in eosinophil infiltration and down-regulate TH1-type cytokine activity. IL-5 plays a key role in the development, activation, and cell survival of eosinophils. In contrast IFN-γ inhibits IgE synthesis as well as the proliferation of TH2 cells and expression of the IL-4 receptor on T cells [8]. The decreased IFN-γ produced by T-cells from AD patients may be the result of reduced production of IL-18 [21].

TH2 immune response in AD is supported by a number of determinants. These include the cytokine milieu in which T cell development is taking place, pharmacologic factors, the co-stimulatory signals used during T cell activation, and the Antigen-Presenting Cell (APC).

Mononuclear cells from patients with AD have increased cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) enzyme activity [22]. This cellular abnormality contributes to the increased IgE synthesis by B cells and the IL-4 production by T cells in AD as IgE and IL-4 production is decreased in vitro by PDE inhibitors.

Co-stimulatory signals, for example, interactions between CD80 or CD86 on APCs and CD28 on T cell receptors with the MCH plus peptide complex on APC in order to activate resting T cells. The expression of the co-stimulatory molecule, CD86, on B cells of AD patients is significantly higher than in normal patients. Importantly, total serum IgE from AD patients and normal subjects correlated significantly with CD86 expression on B cells. Anti-human CD86 significantly decreased IgE production by peripheral blood mononuclear cells stimulated with IL-4 and anti-CD40mAb. These data support the concept that CD86 expression in AD promotes IgE synthesis. IL-4 and IL-13 have also been found to induce CD86 expression on B cells, thereby providing an amplification loop for IgE synthesis in AD [23,24].

Skin Immunopathology

Cytokine expression

Acute lesions are characterized by lymphocytic infiltrate which consists predominantly of activated memory T cells and have significantly greater number of cells producing IL-4, IL-5 and IL-13 but not significant numbers of IFN-γ or IL-12 mRNA expressing cells.

Chronic AD skin lesions have significantly fewer IL-4 and IL-13 mRNA expressing cells, but, greater numbers of IL-5, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) IL-12 and INF-γ mRNA expressing cells than acute AD. IL-5 and GM-CSF probably contribute to the increased numbers of eosinophils and macrophages. The increased expression of IL-12 in chronic AD skin lesions is of interest that cytokine plays key role in IFN-γ production. Its
expression in eosinophils and/or macrophages may initiate the switch to Th1 or Th0 cell development in chronic AD [25].

Activated T cells infiltrating the skin of AD patients have also been found to induce keratinocyte apoptosis which contributes to the spongotic process found in AD lesions [26].

Antigen-presenting cells

AD skin contains an increased number of IgE-bearing LCs, which appear to play an important role in cutaneous allergen presentation to Th2 cells. IgE-bearing LCs that have captured allergens are likely to activate memory Th2 cells in atopic skin but may also migrate to the lymph nodes to stimulate naïve T cells there to expand the pool of systemic Th2 cells [27]. Normal individuals and patients with respiratory allergy have low-level surface expression of FcεRI on their LCs, whereas FcεRI is expressed at high levels in the inflammatory environment of AD. High-level FcεRI expression enhances not only binding and uptake of allergens but the activation of LCs upon receptor ligation. LCs in the lesional skin of AD predominantly express CD86 as compared to CD80 [28,29]. These data suggest that CD86 expression on LCs plays an important role as co-stimulatory molecules for T cell activation and may account for the increased Th2 responses that occur after repeated antigen presentation by LCs.

Inflammatory cell infiltration

In acute AD skin lesions IL-16, a chemoattractant for CD4+ T cells, is increased [30,31]. The C-C chemokines, RANTES, monocyte chemotactic protein-4, and eotaxin have also been found to be increased in AD skin lesions and likely contribute to the chemotaxis of eosinophils and Th2 lymphocytes into the skin [32,33]. Several studies suggest a role for cutaneous T cell-attracting chemokine (CTACK/CCL27) in the potential attraction of CLA+ T cells to skins [34]. The chemokine receptor CCR3, which is found on eosinophils and Th2 lymphocytes and can mediate the action of eotaxin, RANTES, and MCP-4, has been reported to be increased in non-lesional and lesional skin of patients with AD [35].

Acute and chronic skin inflammation

The pathogenesis of AD is not absolutely clear. Immune response in AD skin may be elicited by multiple triggers, such as aeroallergens and food allergens. APCs that have captured allergens are likely to activate Th2 cells which secrete numerous cytokines, such as IL-4, IL-5, IL-10 and IL-13. Activation of B lymphocytes by IL-4 and IL-13 induce IgE synthesis. IL-5 is mainly responsible for activation and survival of eosinophils.

In the past AD was considered a disease induced by Th2 lymphocytes. It has now been demonstrated that in AD skin biphasic response occurs. After an initial Th2 response a switch from Th2 to Th1 response may occur within a few days.

Chronic AD lesions are linked to the prolonged survival of eosinophils and monocyte-macrophages in atopic skin. IL-5 expression during chronic AD likely plays a role in prolonging eosinophil survival and enhancement of their function. In chronic AD an increased GM-CSF expression plays an important role in maintaining the survival and function of monocytes, LCs and eosinophils [36]. Epidermal keratinocytes from AD patients have significantly higher levels of RANTES expression following stimulation with tumor necrosis factor (TNF)-α and IFN-γ than keratinocytes from psoriasis patients. This may serve as one mechanism by which the TNF-α and IFN-γ production during chronic AD enhances the chronicity and severity of eczema. Mechanical trauma can also induce the release of TNF-α and many other pro-inflammatory cytokines from epidermal keratinocytes. Thus, chronic scratching plays a role in the perpetuation and elicitation of skin inflammation in AD [37].

Diagnosis and differential diagnosis

The American Academy of Dermatology has suggested the following universal diagnostic criteria for atopic dermatitis [38].

A. Essential features which must be present and, if complete, as sufficient for diagnosis:

1. Pruritus
2. Eczematous changes that are acute, sub-acute, or chronic:
   a. Typical and age-specific patterns:
      i. Facial, neck, and extensor involvement in infants and children
      ii. Current or prior flexural lesions in adults/any age.
   iii. Sparing of groin and axillary regions
3. Chronic or relapsing course

B. Important features that are seen in most cases, adding support to the diagnosis:

1. Early age at onset
2. Atopy (IgE reactivity)
3. Xerosis

C. Associated features: Clinical associations; help in suggesting the diagnosis of AD but are too nonspecific to be used for defining or detecting AD for research and epidemiologic studies:

1. Keratosis pilaris/Ichthyosis/Palmar hyperlinearity
2. Atypical vascular responses
3. Perifollicular accentuation/Lichenification/Prurigo
4. Ocular/Periorbital changes
5. Perioral/periauricular lesions

Exclusions: Firm diagnosis of AD depends on excluding conditions such as scabies, allergic contact dermatitis, seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, and other primary disease entities.

Table 1 lists a number of inflammatory skin diseases, immunodeficiencies, skin malignancies, genetic disorders, infectious diseases and infestations that share symptoms and signs with AD. These should be considered and ruled out before a diagnosis of AD is made [39].

Immunologic Triggers

Bacteria, viruses, fungi

Patients with AD have an increased tendency to develop bacterial, viral and fungal skin infections. *S. aureus* is found in over 90% of AD skin lesions. One strategy by which *S. aureus* exacerbates or maintains skin inflammation in AD is by secreting a group of toxins known to act as superantigens, which stimulate marked activation of T' cells and macrophages. Most AD patients make specific IgE antibodies directed against the staphylococcal superantigens found on their skin [40].
caused clinical symptoms in younger patients with AD. Milk, eggs and \textit{allergy}. Subsequent studies confirmed that a limited number of foods oral food challenges, 37\% of these patients were diagnosed with food children with moderate to severe AD. After an evaluation including healthy control subjects [43].

Infections and infestations
- Scabies
- Human immunodeficiency virus-associated dermatitis
- Dermatophytosis

Immunodeficiencies
- Wiskott-Aldrich syndrome
- Severe combined immunodeficiency syndrome
- Hyper-IgE syndrome

Autoimmune disorders
- Dermatitis herpetiformis
- Pemphigus foliaceus
- Graft-versus-host disease
- Dermatomyositis

Metabolic disorders
- Zinc deficiency
- Pyridoxine (vitamin B6) and niacin
- Multiple carboxylase deficiency
- Phenylketonuria

Congenital disorders
- Netherton’s syndrome
- Familial keratosis pilaris

Malignancies
- Cutaneous T cell lymphoma (mycosis fungoides/Sézary syndrome)
- Letterer-Siwe disease

Table 1: Differential Diagnosis of Atopic Dermatitis.

The double-stranded DNA viruses, including Herpes Simplex Virus (HSV), molluscum contagiosum virus, and vaccinia virus are also capable of causing more severe and generalized infections in patients with AD [41].

Eczema herpeticum is a disseminated cutaneous form of HSV and is often considered a medical emergency necessitating prompt systemic antiviral therapy. These data suggest that patients with AD with greater Th2 might be at greater risk for cutaneous infections that require a robust Th1 response.

There is considerable evidence that subjects with AD have an unusual propensity for colonization by certain pathogens such as yeast belonging to the genera Malassezia and Candida. A Swedish multicenter study of 132 subjects with AD revealed that 60\% had a positive skin test response to Malassezia species in comparison with no positive test responses in the non-atopic subjects [42].

Additionally, Candida species have been isolated more commonly from the skin of those with AD compared with those with psoriasis and healthy control subjects [43].

The role of food allergy in the development of AD

Food allergy has been strongly correlated with the development and persistence of AD, especially during infancy and early childhood. Eigenmann et al. assessed the prevalence of food allergy among children with moderate to severe AD. After an evaluation including oral food challenges, 37\% of these patients were diagnosed with food allergy. Subsequent studies confirmed that a limited number of foods caused clinical symptoms in younger patients with AD. Milk, eggs and peanuts generally cause more than 75\% of the IgE-mediated reactions. If soy, wheat, fish and tree nuts are added to this list of foods, more than 98\% of the foods that cause clinical symptoms would be identified.

The medical history is helpful in establishing diagnosis in cases of immediate-type hypersensitivity reactions with rapid onset of symptoms after apparent ingestion of a certain food. Diagnostic problems may occur in delayed-type hypersensitivity reactions where the adverse reaction to food is not easily identified and when environmental triggers, such as allergens, irritants, infection lead to exacerbations of the disease, thus covering symptoms elicited when consuming the implicated foods. In addition, repeated exposure to the offending food allergens reduces immediate-type hypersensitivity responses, thus making the cause-effect relationship less easy to identify. For breast-fed infants, a maternal dietary history may be helpful because of the passage of food proteins in breast milk [44].

The best general diagnostic approach is to screen children with moderate to severe AD for sensitivity to eggs, milk, peanuts, soy, wheat, fish and tree nuts (walnut, cashew, pecan) by using skin prick tests or RAST with additional testing for other suspected foods obtained by the history or given by the patients [44,45]. Specific IgE antibodies, prick tests and the history sometimes do not correlate with clinical observations. Therefore, food challenges are necessary to show the clinical relevance of the findings. The skin must be scored by an established eczema score before food challenge, 24 h after and later because otherwise worsening of eczema will be missed [46].

The SCORAD Index (Scoring Atopic Dermatitis Index) is the most commonly used clinical tool to assess the extent and severity of eczema (Table 2) [47]. An objective SCORAD score can be used to determine the severity grading for atopic dermatitis into 3 categories: mild (objective SCORAD<15), moderate (objective SCORAD: 15–40) and severe objective SCORAD>40.

Management

The clinical algorithms for the management of mild-moderate and severe AD is shown in Figures 3 and 4 respectively [48].

Topical Treatment

Cutaneous hydration

Patients with AD have marked decrease in skin barrier function.
associated with reduced ceramide levels and enhanced transepidermal water loss. This leads to dry skin (xerosis) contributing to disease morbidity by the development of microfissures and cracks, which serve as portals of entry for skin pathogens, irritants, and allergens. Lukewarm soaking baths for at least 20 minutes, followed by the application of an occlusive emollient to retain moisture can give patients excellent symptomatic relief. Use of an effective emollient combined with hydration therapy will help to restore and preserve the stratum corneum barrier [49,50].

**Topical steroids**

Topical corticosteroids and calcineurin inhibitors are used as topical anti-inflammatory agents. Steroids may differ in potency based not only on the active ingredient of the drug but also on the vehicle in which they are formulated. A given concentration of a topical steroid is more potent in an ointment than in a cream. The classification of topical corticosteroids based on potency is shown in Table 3 [51,52].

Glucocorticoids have been the cornerstone of anti-inflammatory treatment for over 50 years. Because of potential side effects, most physicians use topical glucocorticoids for control of acute exacerbation of AD. However, studies suggest that once control of AD is achieved with daily regimen of topical glucocorticoid, long-term control can be maintained with twice-weekly applications of topical fluticasone to areas that have healed but are prone to developing eczema [53].

Patients should be carefully instructed in the use of topical glucocorticoids to avoid side effects. Topical glucocorticoids should be applied to the skin lesions and emollients should be used over uninvolved skin. Because of their potential side effects the ultrahigh-potency glucocorticoids should be used only for very short periods of time and in areas that are lichenified, but not on the face or intertriginous areas. The goal is to use emollients to enhance skin hydration and lower-potency glucocorticoids for maintenance therapy.
crease to the tip of the index finger of an adult. The FTU is particularly
from a tube with a 5 mm diameter nozzle, applied from the distal skin-
amount of ointment, cream or other semi-solid dosage form expressed
apply in different parts of the body. A fingertip unit is defined as the
Fingertip Units (FTU) to measure the amount of drug they need to
who are prescribed steroids or calcineurin inhibitors are advised to use
of the state of the child’s skin by the physician (Table 4) [56]. Patients
[55].
eczema. Local burning sensation has been the only common adverse event
cause cutaneous atrophy and has been used safely for facial and eyelid
adults. Unlike topical corticosteroids, tacrolimus ointment does not
term use in moderate-severe AD for children 2 to 15 years of age and
keratinocytes. Tacrolimus ointment has been approved by the Food
of key cells involved in AD, including T cells, LCs, mast cells, and
binding to FK binding protein, inhibits the activation of a number
Topical calcineurin inhibitors
Calcineurin inhibitors (tacrolimus and pimecrolimus) have been
successfully used in the treatment of AD. Pimecrolimus inhibits Th1
and Th2 cytokine production, reduces antigen-presenting capacity of
dCs, mast cells and basophils. Pimecrolimus cream ointment has been
approved by the FDA for short-term and intermittent long-term use in
mild-moderate AD for patients 2 years of age and over [54].

Topically applied tacrolimus, a calcineurin inhibitor that acts by
binding to FK binding protein, activates the inhibition of a number of
key cells involved in AD, including T cells, LCs, mast cells, and
keratinocytes. Tacrolimus ointment has been approved by the Food
and Drug Administration (FDA) for short-term and intermittent long-
term use in moderate-severe AD for children 2 to 15 years of age and
adults. Unlike topical corticosteroids, tacrolimus ointment does not
cause cutaneous atrophy and has been used safely for facial and eyelid
eczema. Local burning sensation has been the only common adverse event
[55].

Treatment of atopic eczema should be based on a “stepped-care plan”
where treatments are stepped up or down depending on the assessment
of the state of the child’s skin by the physician (Table 4) [56]. Patients
who are prescribed steroids or calcineurin inhibitors are advised to use
Fingertip Units (FTU) to measure the amount of drug they need to
apply in different parts of the body. A fingertip unit is defined as the
amount of ointment, cream or other semi-solid dosage form expressed
from a tube with a 5 mm diameter nozzle, applied from the distal skin-
crease to the tip of the index finger of an adult. The FTU is particularly
useful when counseling patients with regards to the amount of topical
anti-inflammatory agent they should be applying in order to minimize
the side-effects which are associated with their use. The amount of
topical anti-inflammatory agent in FTUs that should be applied
according to the child’s age is shown in Figure 5 [56].

Systemic Therapy
Systemic glucocorticoids
The use of systemic glucocorticoids, such as oral prednisone, is rarely indicated in the treatment of chronic AD. The dramatic
improvement that may occur with systemic glucocorticoids is frequently associated with a severe rebound flare of AD following
the discontinuation of systemic glucocorticoids. Short courses of oral
glucocorticoids may be appropriate for an acute exacerbation of AD while other treatment measures are being instituted. If a short course of
oral glucocorticoids is given, it is important to taper the dosage and
begin intensified skin care, particularly with topical glucocorticoids and
frequent bathing followed by application of emollients in order to
prevent rebound flaring of AD [48].

Intravenous immunoglobulin
Intravenous Immunoglobulin has been reported to reduce skin inflammation in patients with refractory AD. The benefits of
intravenous immunoglobulin therapy in AD, however, can be rather
short-lived, that is, the effects are gone within 3 weeks. Therefore, it
is important to intensify local skin care in combination with such
alternative therapies [57].

Interferon-γ
Interferon-γ is known to suppress IgE responses and down-regulate
Th2 cell proliferation and function. Reduction in clinical severity of AD
was correlated with the ability of INF-γ to decrease total circulating
eosinophil counts [48].

Cyclosporine
Cyclosporine is a potent immunosuppressant drug that acts primarily
on T cells by suppressing cytokine transcription. Multiple studies have

---

**Table 3:** Classification of topical steroids based on potency [67].

<table>
<thead>
<tr>
<th>Class</th>
<th>Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Mild</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>0.5-1.0%</td>
</tr>
<tr>
<td>Hydrocortisone acetate</td>
<td>0.5-1.0%</td>
</tr>
<tr>
<td>II</td>
<td>Moderate</td>
</tr>
<tr>
<td>Aclofram ointment</td>
<td>0.05%</td>
</tr>
<tr>
<td>Betamethasone valerate</td>
<td>0.02%</td>
</tr>
<tr>
<td>Betamethasone valerate</td>
<td>0.05%</td>
</tr>
<tr>
<td>Triamcinolone acetate</td>
<td>0.02%</td>
</tr>
<tr>
<td>Triamcinolone acetate</td>
<td>0.05%</td>
</tr>
<tr>
<td>III</td>
<td>Potent</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>0.05%</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>0.1%</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>0.1%</td>
</tr>
<tr>
<td>Mometasone furoate</td>
<td>0.1%</td>
</tr>
</tbody>
</table>

**Table 4:** Treatment of atopic eczema based on a “stepped care plan”.

Step 1: clear skin. Use emollients only.
Step 2: mild-areas of dry skin, and infrequent itching. Use emollients alone or combined with a topical steroid of mild potency.
Step 3: moderate-areas of dry skin, frequent itching and redness. Use emollients with a topical steroid of moderate potency (7-14 days, face 3-5 days use), bandages. (Then a topical calcineurin inhibitor such as tacrolimus—but only initiated under specialist dermatological supervision).
Step 4: severe-widespread areas of dry skin, incessant itching, and redness. Use emollients, potent topical steroids (moderate potency on the face or neck), bandages, (then tacrolimus, phototherapy or systemic treatment—but only initiated under specialist dermatological supervision).

---

**Figure 5:** The amount of topical anti-inflammatory agent in FTUs that should be applied according to the child’s age [56].
demonstrated that patients with severe AD, refractory to conventional treatment, can benefit from short-term cyclosporine treatment with reduced skin disease. However, discontinuation of treatment generally results in rapid relapse of skin disease. Elevated serum creatinine or more significant renal impairment and hypertension are specific side effects that are of concern when cyclosporine is used.

Although viral and fungal infections have an increased tendency to develop in AD skin lesions the most common cause of an exacerbation is colonization of AD skin lesions with S. aureus. A combination of topical or systemic antibiotics and topical corticosteroids result in greater reduction in severity of skin disease compared to topical corticosteroids alone [48].

General aspects on AD management

General measures include the avoidance of alkaline soaps which should be replaced by neutral or acidic, as well as avoidance of trigger factors, such as irritants (e.g. detergents), allergens, pathogenic microorganisms and stress.

In cases of moderate or severe eczema the use of antimicrobial cleansers twice a week will unload the increased microbial colonization and contribute substantially to the control of exacerbations [56].

Emollients

When the diagnosis is definite they should be prescribed in large quantities. In infants they may replace soap or shampoo.

Topical steroids

A patient should be advised to use mild potency steroids for the face and the neck. However, exception can be made for severe flares which may benefit from short-term (3-5 days) use of moderate potency steroids. Steroids of moderate potency or potent corticosteroids are indicated for short periods only (7-14 days) for flares in vulnerable sites such as axillae and groin. If a mild or moderate topical steroid has not controlled the eczema within 7-14 days, the presence of a secondary bacterial or viral infection should be considered. If a potent steroid fails to work over a short time then the child should be referred to a dermatologist [56].

Antihistamines

Non-sedating antihistamines can be used for a month in children with severe eczema or in children with mild/moderate eczema who suffer from severe itching or urticaria. If the trial is successful it should be continued. A 1-2 week course of a sedating antihistamine can be used for an acute flare of dermatitis, where the child’s sleep is being affected [56].

Infections

Parents should be given information about how to recognize flares and start treatment for flare-ups. Symptoms or signs, such as crying, irritability, blistering the skin, or sudden worsening of the rash may indicate an AD exacerbation.

A skin culture should be obtained if there is suspicion for skin infection other than S. aureus possibly resistant to antibiotics. Localized infections may be treated with the use of topical antibiotics as monotherapy or combined with topical steroids, while an extensive skin infection should be managed with a systemic antibiotic regimen.

In all cases of severe eczema exacerbation an infection with herpes simplex—that is, eczema herpeticum—should be considered.
Omalizumab immunotherapy

A study which investigated the efficacy of omalizumab in moderate-severe AD in a target population of 20 adults identified that only a subgroup of patients can benefit from omalizumab treatment. All responders were non-fillagrin mutation carriers indicating that the patients with a primary skin barrier deficiency are less likely to benefit from an immunomodulatory therapy with anti-IgE. However, more extended and controlled studies are needed to validate the previous assumption [64].

Allergen specific immunotherapy for AD

Allergen-specific immunotherapy (allergen-SIT) is the only treatment directed at the cause of IgE-mediated diseases. The effects of SIT for patients with atopic dermatitis have been investigated by a systematic review and meta-analysis of Randomized Controlled Trials (RCTs). A total of 219 patients were included in the SIT groups and 166 patients in the control groups. The results showed that SIT had a significantly positive effect on AD for all 8 RCTs analyzed. Although the previous findings are based on an analysis of a small number of RCTs, with considerable heterogeneity among trials, the review provides physicians with evidence necessary to consider allergen-SIT for patients with AD, especially those with severe uncontrolled disease [65].

Prognosis

A large prospective longitudinal cohort study of more than 7000 children with mild to moderate AD, which provided 5 years follow-up, reported lack of resolution. Remission occurred in approximately 15% of the population. It is probable that AD does not fully resolve in most children with mild to moderate symptoms. Physicians who treat children with mild to moderate AD should tell children and their caregivers that AD is a lifelong illness [66,67].

References
